Understanding genetic variation in in vivo tolerance to artesunate: implications for treatment efficacy and resistance monitoring

Evolutionary Applications

Laura C. Pollitt¹  Derek Sim¹  Rahel Salathé¹ 

[1] Center for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park, PA, USA

关键词: artemisinin;    clearance rates;    drug resistance;    genetic variation;    malaria;    Plasmodium chabaudi;   

DOI  :  10.1111/eva.12194

来源: Wiley

【 摘 要 】

Abstract

Artemisinin-based drugs are the front-line weapon in the treatment of human malaria cases, but there is concern that recent reports of slow clearing infections may signal developing resistance to treatment. In the absence of molecular markers for resistance, current efforts to monitor drug efficacy are based on the rate at which parasites are cleared from infections. However, some knowledge of the standing variation in parasite susceptibility is needed to identify a meaningful increase in infection half-life. Here, we show that five previously unexposed genotypes of the rodent malaria parasite Plasmodium chabaudi differ substantially in their in vivo response to treatment. Slower clearance rates were not linked to parasite virulence or growth rate, going against the suggestion that drug treatment will drive the evolution of virulence in this system. The level of variation observed here in a relatively small number of genotypes suggests existing ‘resistant’ parasites could be present in the population and therefore, increased parasite clearance rates could represent selection on pre-existing variation rather than de novo resistance events. This has implications for resistance monitoring as susceptibility may depend on evolved traits unrelated to drug exposure.

【 授权许可】

CC BY   
© 2014 The Authors. Evolutionary Applications published by John Wiley & Sons Ltd.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.